Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02155218 · ClinicalTrials.gov registry record · NA
Improving the Concentration of MR Contrast in the Arteries
A NA study, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
NCT02155218: Completed NA study, sponsored by University of Washington.
NCT02155218 is a NA study that has completed, run by University of Washington. The registered enrollment target is 26 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02155218, a NA study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
Study Summary
In Contrast-Enhanced Magnetic Resonance Angiography (CE-MRA) a contrast agent is injected into an arm vein using a programmable medical device called a power injector. Once the contrast has circulated to the blood vessel of interest they can be imaged with MRI and distinctly separated from surrounding non-vascular tissue. This project is designed to find the best way to administer the contrast agent during CE-MRA to produce the best images. The clinical availability of programmable power injectors facilitates the use of variable contrast rate and volume injection protocols that are based on patient specific parameters. CE-MRA is a valuable imaging tool for diagnosing abnormalities of the major blood vessels in the chest and abdomen. It is often used in conjunction with cardiac magnetic resonance (CMR) examinations to evaluate the blood vessels of the heart and lung. CE-MRA is attractive because 1) it does not involve radiation, and 2) the contrast agents used are not toxic to the kidneys and can be used in patients who are at greater risk for kidney dysfunction following iodinated contrast agents. We plan to administer a small (1cc) test amount of contrast, taking pictures as the contrast passes through the blood vessels, and analyze the results. Using this information, we will administer an individually patient-tailored injection given in multiple phases (i.e., a "multi-phasic" injection) to maintain constant contrast concentration (and therefore constant signal intensity) throughout the scan. We believe this will reduce image blurring, and improve the sharpness and likely the diagnostic quality of CE-MRA.
Primary Outcome
To evaluate the performance of the bolus-tailoring method, measured signal intensity profiles will be evaluated using residual sum-of-squares (RSS) between targeted and measured responses. A smaller RSS indicates agreement with the targeted signal intensity profile. Additionally, full-width-at-half-maximum (FWHM) and start time (10% signal intensity increase over baseline) of the signal intensity profile will be measured and compared between the two groups. T-test will be used to test for signif
Interventions
- OTHER Standard Injection Rate
- OTHER Patient Tailored Injection Rate
- OTHER gadolinium contrast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-11 |
| Phase | NA |
What the finished NCT02155218 record still lists
NCT02155218 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Standard Injection Rate is the first listed.
NCT02155218 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02155218 about?
NCT02155218 is a clinical study titled "Improving the Concentration of MR Contrast in the Arteries". In Contrast-Enhanced Magnetic Resonance Angiography (CE-MRA) a contrast agent is injected into an arm vein using a programmable medical device called a power injector. Once the contrast has circulated to the blood vessel of interest they can be imaged with MRI and distinctly separated from surroundi...
What is the current status of trial NCT02155218?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2014-06. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02155218?
The interventions under investigation include: Standard Injection Rate (OTHER), Patient Tailored Injection Rate (OTHER), gadolinium contrast (OTHER).
Who is sponsoring clinical trial NCT02155218?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02155218's enrollment target sits among peer trials
26 1710th of 2000 higher than 289 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia